Physician profile
Mark Tan
NPI 1639755150
$1,362.17
in general payments reported to CMS, 2019-2025
9 companies · $581 in 2025
The $581 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $261 · 2024: $520 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,362.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $439.68 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $313.99 | 2024-2025 | |
| Abbott Laboratories | $260.75 | 2023 | Freestyle Libre 3 |
| Pfizer INC. | $76.78 | 2025 | |
| Novo Nordisk INC | $67.71 | 2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $63.72 | 2024-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $48.74 | 2024-2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $47.72 | 2025 | Injectafer |
| Astellas Pharma US INC | $43.08 | 2025 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.